ASH 2025: Myelofibrosis Roundup - Summary - MDSpire
Conference News

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

Share

The treatment landscape for myelofibrosis is shifting as new therapies, notably combinations with JAK inhibitors and novel agents, show promising results. Major findings presented at the 2025 ASH Annual Meeting highlight the efficacy of pelabresib plus ruxolitinib in JAK inhibitor-naive patients, demonstrating significant improvements in spleen volume and safety profiles. Other studies, including elritercept's results paired with ruxolitinib for patients with anemia, indicate robust efficacy. Meanwhile, stem cell transplantation remains a curative option for high-risk patients, reinforcing the importance of precise management strategies for optimization.

Original Source(s)

ASH 2025: Myelofibrosis Roundup

  • by Caroline Helwick

  • March 24, 2026

Related Content

Rare COVID Vaccine Clotting Linked to Adenoviral Protein 

Antibody proteomics and immunogenetics identify adenoviral protein VII as the trigger of PF4-targeting antibodies 

  • April 21, 2026

  • 2 min
Gene Therapy for Sickle Cell Could Be Cost-Effective in Uganda

New modeling study shows curative treatments may be viable in low-income settings if costs are scaled and societal benefits included

  • April 9, 2026

  • 2 min
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...